GENENTECH, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1976-01-01

Employees: 11.1K

Market Cap: -

Website: http://www.gene.com

Clinical Trials

A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function

Phase 1

Not yet recruiting

Conditions: Hepatic Impairment

Interventions: Drug: Divarasib

First Posted Date: 2024-12-16

Last Posted Date: 2024-12-16

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 40

Registration Number: NCT06734208

A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis

Phase 1

Not yet recruiting

Conditions: Moderate to Severe Ulcerative Colitis

Interventions: Drug: Vixarelimab

First Posted Date: 2024-11-18

Last Posted Date: 2024-11-18

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 24

Registration Number: NCT06693908

A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: Divarasib
Drug: Itraconazole

First Posted Date: 2024-11-15

Last Posted Date: 2024-12-16

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 18

Registration Number: NCT06690138

Locations: 🇺🇸
Dallas Clinical Research Unit, Dallas, Texas, United States

A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants

Phase 1

Active, not recruiting

Conditions: Healthy Participants

Interventions: Drug: Digoxin
Drug: Rosuvastatin
Drug: Divarasib

First Posted Date: 2024-11-07

Last Posted Date: 2024-12-05

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 19

Registration Number: NCT06677957

Locations: 🇺🇸
Daytona Beach Clinical Rsch Unit, Daytona Beach, Florida, United States

Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration

Phase 1

Active, not recruiting

Conditions: Age-Related Macular Degeneration

Interventions: Biological: OpRegen

First Posted Date: 2024-11-05

Last Posted Date: 2024-11-05

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 24

Registration Number: NCT06674993

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: Phase I Arm A
Drug: Phase I Arm B

First Posted Date: 2024-10-01

Last Posted Date: 2024-12-09

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 410

Registration Number: NCT06619587

Locations: 🇦🇺
St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia
🇦🇺
Peter MacCallum Cancer Center, Melbourne, Victoria, Australia

A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)

Phase 2

Not yet recruiting

Conditions: Acute Kidney Injury

Interventions: Drug: Placebo
Drug: GDC-8264

First Posted Date: 2024-09-19

Last Posted Date: 2024-09-19

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 404

Registration Number: NCT06602453

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-Obstructive Disease

Phase 1

Recruiting

Conditions: Non Cystic Fibrosis Bronchiectasis
Chronic Obstructive Pulmonary Disease

Interventions: Drug: GDC-6988

First Posted Date: 2024-09-19

Last Posted Date: 2024-11-26

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 128

Registration Number: NCT06603246

Locations: 🇺🇸
Texas Research Institute/TTS, Boerne, Texas, United States

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-Line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-Treatment Period.

Phase 2

Recruiting

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Venetoclax
Drug: cBTKi Monotherapy

First Posted Date: 2024-07-29

Last Posted Date: 2024-12-05

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 100

Registration Number: NCT06524375

Locations: 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
University Cancer and Blood Center, LLC, Athens, Georgia, United States
🇺🇸
American Oncology Partners of Maryland, Pa, Bethesda, Maryland, United States

and more 10 locations

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumour

Interventions: Drug: RO7759065
Drug: Atezolizumab

First Posted Date: 2024-07-05

Last Posted Date: 2024-12-19

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 310

Registration Number: NCT06488716

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy